ArticlePloS one2024

Cost-effectiveness analysis of olaparib maintenance therapy for BRCA mutation ovarian cancer in the public sector in Malaysia.

Chee Meng Yong et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.